(Daily Signal)—For years, pharmaceutical executives have insisted that drug prices are out of their hands. Government red tape, research costs, and reimbursement rules are all offered as explanations for why Americans pay more at the pharmacy counter than anyone else in the developed world.
It’s a tidy narrative. It’s also only half-true—pharma could easily drop its prices. But government has ensured that it has little reason to do so.
In a functioning market, companies charge what the market will bear. Those prices typically lower over time due to innovation, competition, and other factors. In only a few industries has the opposite happened—housing, higher education, and health care—all industries where incentives are skewed by government policies.
In the pharmaceutical industry, many factors create market disincentives. For example, U.S. taxpayers contribute roughly $17 billion each year to early-stage research and clinical studies, yet companies still price their products as if every cost rests solely on their own books. In most industries, a subsidy of that size would reduce the final price of a product. In pharmaceuticals, it has done the opposite.
Then there’s the government-guaranteed demand. Schools and the military require routine vaccinations, while federal insurance programs cover millions of prescriptions. These are not competitive markets. They are compelled markets where suppliers face little risk of losing large blocks of customers.
Whenever demand is guaranteed by federal or state policy, the incentive to price competitively weakens. A market that cannot walk away is a market that pays more.
Finally, we have patent abuse, where pharmaceutical companies create virtual monopolies by extending patents for critical and life-saving drugs again and again (and again), far beyond reason and beyond what many patients can afford.
Most industries do not enjoy this combination of subsidized research and guaranteed large scale buyers. A restaurant chain cannot rely on federal dollars to cover its early expansion. A tech startup cannot demand that public schools purchase its software. An airline cannot treat government agencies as automatic customers who have no alternative suppliers.
They all compete in markets where price is constrained by consumer choice and competitive pressure.
The irony is that pharma companies are behaving exactly as economic theory predicts. Again, students complain about high college prices—but they keep going up because of government loan, scholarship, and other policies that bring in billions as long as students can be convinced to sign the dotted line.
The same is true in housing, where well-intentioned government homeownership goals have created poor incentives for lenders and buyers alike (see the 2007 financial crash for an example of what happens when those incentive-created bubbles eventually pop).
The problem is not that companies follow incentives. The problem is that the incentives in the pharma market are distorted by public policy choices that tilt the field in one direction.
The lesson for policymakers and the public is straightforward. If we want a drug market that behaves like a market, we must design one. That means aligning research incentives with affordability and rethinking mandates that guarantee revenue without requiring accountability.
A firm’s first obligation is to its owners. If the structure of a market allows it to raise prices, reduce competition or shield revenue, the firm is expected to pursue those advantages.
And there is nothing inherently wrong with companies pursuing profit. But there is something wrong with a system that shields them from the competitive forces that keep other industries honest.
When companies say they can’t lower prices, it usually means that they simply don’t want to. But prices are choices made by all market players—such as consumers, manufacturers, and government regulators.
The sooner we acknowledge that prices are not set in stone, the sooner Americans can stop footing the bill for a pharmaceutical system that pretends otherwise.
JD’s manually curated links for God-fearing MAGA patriots
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.